730
Participants
Start Date
August 18, 2021
Primary Completion Date
March 22, 2027
Study Completion Date
March 22, 2027
Pembrolizumab
Pembrolizumab 400 mg administered Q6W via IV infusion
Belzutifan
Belzutifan 120 mg administered QD via oral tablet
Lenvatinib
Lenvantinib dose for HCC is 8 mg QD for body weight \<60 kg and 12 mg QD for body weight ≥ 60 kg administered via oral capsule. For all other tumors, the lenvatinib dose is 20 mg QD administered via oral capsule
Auckland City Hospital-Liver Research Unit ( Site 4201), Grafton
Auckland City Hospital-Cancer & Blood Research ( Site 4200), Auckland
Cliniques universitaires Saint-Luc-Medical Oncology ( Site 1001), Brussels
Westmead Hospital-Department of Medical Oncology ( Site 4001), Westmead
Gosford Hospital-Oncology Trials ( Site 4004), Gosford
Antwerp University Hospital-Oncology ( Site 1002), Edegem
UZ Leuven ( Site 1000), Leuven
Northern Hospital-Department of Medical Oncology ( Site 4003), Epping
Cabrini Hospital - Malvern-Cabrini Institute ( Site 4000), Malvern
Université Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 1003), Namur
AZ Delta vzw ( Site 1004), Roeselare
Memorial Sloan Kettering Cancer Center ( Site 5050), New York
CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 1807), Santiago de Compostela
Sibley Memorial Hospital ( Site 5051), Washington D.C.
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - GI and Immunology ( Site 5048), Baltimore
Inova Schar Cancer Institute ( Site 5039), Fairfax
Blue Ridge Cancer Care ( Site 5053), Roanoke
CHU Besançon-Medical oncology ( Site 1101), Besançon
Duke Cancer Institute ( Site 5026), Durham
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 1801), Madrid
CHU Brest Cavale Blanche ( Site 1107), Brest
University of Florida College of Medicine ( Site 5015), Gainesville
Hospital Universitario Central de Asturias-Medical Oncology ( Site 1802), Oviedo
Institut Regional du Cancer Montpellier ( Site 1106), Montpellier
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 1103), Rennes
Centre Hospitalier Universitaire de Grenoble-Medical Oncology ( Site 1105), La Tronche
Keimyung University Dongsan Hospital CRC room 1 ( Site 4104), Daegu
Brigitte Harris Cancer Pavilion ( Site 5055), Detroit
University of Wisconsin Hospitals and Clinics ( Site 5037), Madison
Chonnam National University Hwasun Hospital-Hemato-Oncology ( Site 4105), Hwasun Gun
University of Texas MD Anderson Cancer Center-Gastrointestinal Medical Oncology ( Site 5049), Houston
Sainte Catherine Institut du Cancer Avignon Provence ( Site 1108), Avignon
University of Arizona Cancer Center-University of Arizona Cancer Center - North Campus ( Site 5047), Tucson
Cedars-Sinai Medical Center ( Site 5045), Los Angeles
City of Hope Comprehensive Cancer Center ( Site 5002), Duarte
Hôpital Beaujon-Oncologie Digestive ( Site 1104), Clichy
UCSF Medical Center at Mission Bay ( Site 5021), San Francisco
Northwest Medical Specialties, PLLC ( Site 5025), Tacoma
Rambam Health Care Campus-Oncology ( Site 1300), Haifa
Centro Investigación del Cáncer James Lind ( Site 3107), Temuco
Sheba Medical Center-ONCOLOGY ( Site 1302), Ramat Gan
Clínica Puerto Montt ( Site 3110), Port Montt
Sourasky Medical Center-Oncology ( Site 1301), Tel Aviv
FALP-UIDO ( Site 3102), Santiago
Oncovida ( Site 3108), Santiago
Bradfordhill-Clinical Area ( Site 3100), Santiago
Hadassah Medical Center-Oncology ( Site 1303), Jerusalem
Yale-New Haven Hospital-Yale Cancer Center ( Site 5013), New Haven
Maastricht UMC+-Medical Oncology ( Site 1501), Maastricht
Leids Universitair Medisch Centrum-Medical Oncology ( Site 1504), Leiden
Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 1503), Utrecht
Seoul National University Hospital-Internal Medicine ( Site 4103), Seoul
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 4100), Seoul
Asan Medical Center-Department of Oncology ( Site 4101), Seoul
Samsung Medical Center-Division of Hematology/Oncology ( Site 4102), Seoul
Hospital Germans Trias i Pujol-Instituto Catalán de Oncología de Badalona ( Site 1806), Badalona
Hospital Universitari Vall d'Hebron-Oncology ( Site 1800), Barcelona
Merck Sharp & Dohme LLC
INDUSTRY